Creative Biolabs is a world-leading service provider of application-specific antibody development. Here, we introduce our in vitro diagnostic (IVD) antibody development and immunoassay development services targeting the urotensin II marker. We are confident that our commitment to science and research will enable us to offer you the best products and services.
Urotensin II (UII) is an 11 amino acid peptide originally isolated from the goby fish. The amino acid sequence of UII is exceptionally conserved across most vertebrate taxa, sharing structural similarity to somatostatin. UII and its receptor, UT, are widely expressed throughout the cardiovascular, central nervous, pulmonary, renal, and metabolic systems. UII also exerts a wide range of actions in other systems, such as proliferation of fibroblasts, vascular smooth muscle cells, and cancer cells. It also enhances chemotaxis of inflammatory cells, foam cell formation and hypertrophic effects on heart muscle. Besides, it inhibits insulin release, modulates glomerular filtration, and release of catecholamines.
Fig 1. Schematic of the effects of UII in endothelial cells, vascular SMCs, and macrophages. (Tsoukas, P., 2011)
Urotensin II Marker of Atherosclerosis
Atherosclerosis is often regarded as a principal cause of most cardiovascular diseases and consequently as the leading cause of death in the western world. The role that urotensin II playing in the progression of atherosclerosis is a major and pressing area of current research. In human abdominal aortic aneurysm and carotid atherosclerotic extracts, urotensin II expression is increased. So urotensin II is thought to play autocrine and paracrine roles in the formation of atherosclerotic plaques. Therefore, atherosclerosis can be confirmed by elevating urotensin II levels in plasma. It is becoming increasingly clear through biochemical, animal, and human studies that urotensin II may be a key player in the development of atherosclerosis.
Urotensin II Marker of Renal Disease
There is widespread evidence of urotensin II expression alterations and changes in a number of renal pathologies, including renal failure, nephrotic disorders, and end-stage renal disease. Renal dysfunction in diabetes is associated with higher plasma and urinary levels of urotensin II than in diabetics with normal renal function.
Urotensin II Marker of Metabolic Syndrome
The metabolic syndrome consists of a number of metabolic disturbances that may influence one another. Collectively, these abnormalities are conducive to the development of type 2 diabetes, cardiovascular disease, and eventually, death. The cumulative effects of urotensin II on glucose metabolism and insulin resistance may combine with the pressor, lipogenic, and inflammatory effects in a positive feedback mechanism. Although urotensin II may not be implicated in the initiation of the individual factors comprising the metabolic syndrome, it plays a role in the development of each factor, particularly when coupled to endothelial dysfunction.
IVD Antibody Development Services for Urotensin II Marker
In recent years, IVD technologies are undergoing rapid development. IVD antibodies have been extensively used for the diagnosis of numerous diseases, conditions, or infections. Numerous candidate biomarkers were introduced as specific biomarkers for discrimination of indolent and advanced disease. As a leading service provider in the antibody field, Creative Biolabs provides IVD antibody development services for urotensin II marker for our global customers in the most high-quality and cost-effective way.
If you are interested in the services we provide, please feel free to contact us and get a quote.
Reference
For Research Use Only.
